RecruitingPhase 2NCT06676579

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Fernando Fervenza, MD, M.D
Mayo Clinic, Rochester, MN
Intervention
Avacopan(drug)
Enrollment
16 enrolled
Eligibility
18 years · All sexes
Timeline
20252029

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06676579 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy

← Back to all trials